We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+2.14%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$1.84B
AUM Growth
-$480M
(-21%)
Cap. Flow
-$470M
Cap. Flow
% of AUM
-25.56%
Top 10 Holdings %
Top 10 Hldgs %
46.94%
Holding
98
New
25
Increased
8
Reduced
28
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$106M |
| 2 |
Danaher
DHR
|
+$46.8M |
| 3 |
Johnson & Johnson
JNJ
|
+$44.6M |
| 4 |
Elevance Health
ELV
|
+$42.7M |
| 5 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$33.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$104M |
| 2 |
McKesson
MCK
|
+$83.1M |
| 3 |
Welltower
WELL
|
+$50.9M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$48.6M |
| 5 |
Petco
WOOF
|
+$48.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.78% |
| 2 | Consumer Discretionary | 2.94% |
| 3 | Financials | 1.26% |
| 4 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Medtronic
MDT
$110B
| $158M | 8.62% |
1,530,580
+918,100
| +150% | +$106M |
|
|
2
Bristol-Myers Squibb
BMY
$132B
| $113M | 6.12% |
1,804,550
-1,779,610
| -50% | -$104M |
|
3
Biogen
BIIB
$30.7B
| $109M | 5.92% |
453,400
-13,430
| -3% | -$3.45M |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $89.7M | 4.88% |
832,270
-445,958
| -35% | -$48.6M |
|
5
Envista
NVST
$4.52B
| $74M | 4.03% |
1,642,680
-607,292
| -27% | -$25M |
|
6
Natera
NTRA
$38.6B
| $70.3M | 3.83% |
752,920
-144,726
| -16% | -$15M |
|
7
Cencora
COR
$60.7B
| $69.2M | 3.77% |
520,920
-375,760
| -42% | -$46.2M |
|
8
Tenet Healthcare
THC
$20.3B
| $63.9M | 3.48% |
782,180
-302,060
| -28% | -$22.1M |
|
9
Centene
CNC
$30.1B
| $61.8M | 3.36% |
750,270
-232,360
| -24% | -$17M |
|
|
10
Petco
WOOF
$794M
| $54M | 2.94% |
2,729,450
-2,215,000
| -45% | -$48.4M |
|
11
Boston Scientific
BSX
$68.4B
| $53.7M | 2.92% |
1,263,670
-444,011
| -26% | -$18.7M |
|
|
12
Danaher
DHR
$138B
| $49.5M | 2.7% |
+169,866
| New | +$46.8M |
|
|
13
Johnson & Johnson
JNJ
$617B
| $47.9M | 2.6% |
279,810
+272,530
| +3,744% | +$44.6M |
|
|
14
Elevance Health
ELV
$81.6B
| $47.1M | 2.56% |
+101,560
| New | +$42.7M |
|
15
Jazz Pharmaceuticals
JAZZ
$16.2B
| $44.5M | 2.42% |
349,080
-111,710
| -24% | -$14.7M |
|
16
Stryker
SYK
$133B
| $42.5M | 2.31% |
158,940
-63,570
| -29% | -$16.7M |
|
17
LivaNova
LIVN
$4.45B
| $37.6M | 2.05% |
430,600
-221,550
| -34% | -$18.5M |
|
18
Universal Health Services
UHS
$9.88B
| $37M | 2.02% |
285,620
-63,060
| -18% | -$8.11M |
|
|
19
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
| $35.8M | 1.95% |
+254,230
| New | +$33.8M |
|
20
Cooper Companies
COO
$14.2B
| $33.6M | 1.83% |
+320,520
| New | +$32.6M |
|
|
NVRO
21
DELISTED
NEVRO CORP.
NVRO
| $33.2M | 1.81% |
409,230
-120,000
| -23% | -$12M |
|
22
BioCryst Pharmaceuticals
BCRX
$2.35B
| $32.9M | 1.79% |
2,377,130
-1,472,340
| -38% | -$19.5M |
|
23
Neurocrine Biosciences
NBIX
$18.7B
| $31.1M | 1.7% |
365,737
-80,002
| -18% | -$7.36M |
|
24
Abbott
ABT
$183B
| $28.5M | 1.55% |
+202,710
| New | +$25.9M |
|
|
25
CALL
Medtronic
MDT
$110B
| $28.4M | 1.55% |
+275,000
| New | +$31.8M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q4 2021 Portfolio in Review
As of Q4 2021, HealthCor Management held 98 positions worth $1.84B, down 21% from $2.32B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
HealthCor Management withdrew a net $470M in Q4 2021, closing 30 positions and reducing 28 holdings. Its most notable exit was Welltower, an estimated $50.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 89% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, HealthCor Management opened a new position in Danaher worth $49.5M.
- HealthCor Management's largest Q4 2021 buy was Danaher: 169,866 shares worth $49.5M.
- HealthCor Management added most to Medtronic in Q4 2021, an estimated $106M increase.
- HealthCor Management's biggest Q4 2021 reduction was Bristol-Myers Squibb, cutting an estimated $104M.
- HealthCor Management fully exited Welltower in Q4 2021, selling an estimated $50.9M.
- HealthCor Management's ten largest holdings make up 47% of its $1.84B portfolio in Q4 2021.
- HealthCor Management opened 25 new positions and closed 30 in Q4 2021.
- HealthCor Management's portfolio value fell 21% quarter-over-quarter to $1.84B.
Based on HealthCor Management's 13F filing for Q4 2021, filed 14 Feb 2022.